The purpose of this study is to learn about the associations of symptoms such as fatigue, depression, and gastrointestinal distress including constipation, abdominal pain, and diarrhea with stool microbiomes and metabolites in patients with colorectal cancer. We will compare the associations of symptoms with microbiomes among colorectal cancer patients and healthy patients. You will be asked to complete several surveys that ask questions about your dietary habits, your health history, your social demographics, and your symptoms. You will also be asked to collect a stool sample with an at-home stool sample collection kit that will be provided to you.
- Diagnosed with stage I-IV colorectal cancer (ICD-10 C18, C19 and C20) OR Healthy.
- 18+ years of age at time of diagnosis.
- Able to communicate in English and provide consent.
- African American OR White.
- Not currently in cancer treatment.
- No current ostomy.
- No chronic bowel disorders (e.g., irritable bowel syndrome).
- No diagnosis of functional GI disorders.
- No food allergies or dietary restrictions.
- No use of probiotics or antibiotics within the past two months prior to fecal collection.
- No significant cognitive or developmental delay that precedes cancer diagnosis (e.g., down syndrome, autism spectrum disorder).
The purpose of this study is to better understand why some survivors of breast cancer have difficulty exercising. We also want to learn if breathing exercises can make it easier to tolerate exercise.
- Breast Cancer Survivor
- Completed treatment within 6 months–5 years
- Have obesity, defined as body mass index between 30-50 kg/m2
- Can exercise independently
Our team is looking to improve the health of older cancer survivors after they have completed cancer treatment. Specifically, this 12-week study looks to improve older cancer survivors' physical function and related health outcomes (muscle strength, dietary quality, health-related quality of life, self-efficacy, weight management).
-History of stage I-III breast, colorectal, and prostate cancer
-Completion of curative treatment (chemotherapy, radiation, surgery)
-Have an email address
in a High-Risk Cohort for Lung Cancer
The purpose of the study is to examine the effects of exercise on long-term smokers in reducing lung cancer risk.
- Males and females aged 55 to 77 years old
- Current or former smokers with a 20-pack year smoking history (equals 1 pack a day for 20 years, 2 packs a day for 15 years, etc) and smoked within the last 15 years
- Sedentary Lifestyle: fewer than 60 minutes of participation in moderate intensity physical activity each
- Health Status: participants must be free of severe heart, respiratory (e.g. COPD), or systemic disease that would make moderate intensity exercise participation unsafe
- Not currently undergoing cancer treatment
- Not currently taking Immunosuppressants, bisphosphonates, steroids, or probiotics
- No plan to change smoking status
The purpose of this study is to understand how cancer survivors view the risks and benefits of nicotine and tobacco products.
The duration of the study will last two hours.
- At least 21 years old
- Cancer survivor
- Currently smoking combustible tobacco
- Access to an email address and a phone, tablet, or computer with internet access
- Currently using electronic nicotine delivery systems (e-cigarettes, vape pens, e-hookah, etc.) OR interested in trying them in the future
This study will examine the effect of different e-cigarettes on product appeal.
- A current e-cigarette user
- 21-24 years old
- Willing to attend a study visit
- A current smoker
- 25-50 years old
- Willing to attend a study visit
- Willing to try e-cigarettes
The purpose of this study is to learn more about how to best care for patients who have immune-related side effects and have received treatment with an immune checkpoint inhibitor.
The duration of this study is 30 days.
- Must speak English and/or Spanish
- Diagnosis of cancer (excluding non-melanoma skin cancer)
- Last immunotherapy received within 90 days of study enrollment
The long-term goal of this study is to improve decision quality and health-related outcomes for sexual gender minority (SGM) breast/chest cancer survivors. The goal is to evaluate important ways the current care model needs adjusted for SGM people, and how best to combine a socially important care model into clinical practice.
Survivors: Eligible participants will participate in a 90-minute focus group and online survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.
Clinicians: Eligible participants will participate in a 30-minute interview and brief survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.
Participation in this study will take no more than 1 hour and 30 minutes.
1. Self-identify as a member of the SGM community
2. Age ≥18 years at the time of signing the informed consent form
3. Breast/chest cancer survivor in active treatment or completed active treatment in the last 10 years (not including hormone therapy)
4. Be able to read and speak English
5. Have received care in the U.S.
6. Be able to participate in virtual meetings
1. Physicians, advance practice providers, nurses, psychologists, social workers, therapists, technologists, and other trained clinical professionals
2. Provide care to individuals diagnosed with breast cancer in the U.S.
3. Be able to read and speak English
4. Be able to participate in virtual meetings
To evaluate the cardio-oncology patient population’s experience with using smart-phone technology as a part of self-management with their care through features such as symptom logging and education. Eligible patients will be asked to participate in a 30-minute virtual interview and/or a 60-minute virtual design or usability session to discuss their thoughts on a mobile app for cardio-oncology patients.
- English-speaking - Prior cancer diagnosis - Currently undergoing a cancer regimen that includes a targeted, biologic, radiation, and/or immune-based therapy (ex. TKIs and/or ICIs). - No pregnant females - No prisoners
Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.
- Patient must be age 18 years of age or older. - Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable dosage for ≥ 1 week. - Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue at the same dosage.
- Page 1
- Next page